货号:A134210
同义名:
3,4-Dihydroxycinnamic Acid
Caffeic Acid是一种羟基肉桂酸,一种天然有机化合物,从东南亚植物Boehmeria siamensis Craib的草本中分离提纯,具有抗氧化、抗肿瘤、抗HIV、胆汁促进、肝向性作用,并且是中性粒细胞弹性蛋白酶的强抑制剂。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Caffeic acid is an inhibitor of both TRPV1 ion channel and 5-Lipoxygenase (5-LO). |
| 体内研究 | Mice treated with Caffeic acid at a dose of 500 mg/kg display a marked reduction in histamine-induced scratching behavior, recording an average of 30.50±10.87 bouts per hour, with a sample size of six. A lower dose of Caffeic acid (100 mg/kg) shows a non-significant reduction in scratching, indicating a possible decreasing trend (49.40±12.35 bouts per hour, n=5). Chloroquine-induced scratching is significantly decreased following pretreatment with 500 mg/kg of Caffeic acid, registering 161.6±31.42 bouts per hour in five subjects[1]. Additionally, Caffeic acid substantially lowers the expression of 5-LO mRNA in a dose-dependent manner in the hippocampus. Compared to the ischemia-reperfusion (I/R) untreated group, 5-LO protein expression significantly diminishes in the I/R-Caffeic acid-treated group, particularly at 50 mg/kg. Relative to the I/R untreated group, the time taken to locate the platform significantly decreases in both low- and high-dose Caffeic acid-treated groups, with the most notable reduction in the I/R-Caffeic acid 50 mg/kg group (P<0.01). In the low-dose Caffeic acid group, cell injury remains pronounced with a pyknosis ratio of 63.6±2.8%, while in the high-dose group, hippocampal neuron pyknosis significantly decreases, showing a pyknosis ratio of 13.3±3.0%[2]. |
| 体外研究 | Caffeic acid exhibits inhibitory effects on histamine-induced reactions, with its suppressive impact progressively intensifying at concentrations ranging from 0.1 to 1 mM, indicative of a typical dose-dependent response. In HEK293T-TRPV1 cells, a 1 mM pre-incubation with Caffeic acid significantly curtails capsaicin-triggered responses, whereas at lower concentrations, this inhibitory effect on capsaicin-induced reactions is less pronounced. Calcium imaging experiments reveal that Caffeic acid treatment notably reduces activity in histamine-sensitive dorsal root ganglion (DRG) neurons. With a 1 mM Caffeic acid pretreatment, there is a substantial reduction in the proportion of DRG neurons responsive to histamine, decreasing from 12.5% to 2.1%. Additionally, a 1 mM concentration of Caffeic acid effectively obstructs the intracellular calcium increase induced by allylisothiocyanate (AITC) in TRPA1-expressing cells, also preventing AITC-induced TRPA1 activation[1]. |
| Concentration | Treated Time | Description | References | |
| Bovine mammary epithelial cells | 125 or 250 mg/ml | 12 hours | CA pretreatment inhibited E. coli B1-induced inflammatory responses and oxidative stress, and restored lipid homeostasis. | Front Immunol. 2022 Oct 20;13:1005430. |
| HTB-34 human cervical cancer cells | 100 µM | 24 hours | Caffeic acid activates AMPK, inhibits cell proliferation, and promotes apoptosis | Int J Mol Sci. 2017 Feb 21;18(2):462. |
| Colon myofibroblasts CCD-18Co | 50 µM, 10 µM, 1 µM | 24 hours | Investigated the effects of caffeic acid on COX-2 expression, PGE2 biosynthesis, and inflammatory cytokines/chemokines (IL-8, MCP-1, IL-6) in IL-1β-stimulated colon myofibroblasts. Results: Caffeic acid dose-dependently reduced PGE2 levels (significant at 50 and 10 μM), downregulated COX-2 expression (significant at 50 and 10 μM), and only at 50 μM significantly decreased IL-8 secretion (~27%), with no effect on MCP-1 or IL-6. | Nutrients. 2021 Feb 8;13(2):554. |
| Primary bovine mammary epithelial cells | 10, 25, 50 μg/mL | 3 hours pretreatment followed by LPS stimulation for 12 hours | Caffeic acid protected cells from LPS-induced structural damage and apoptosis by inhibiting NF-κB and MAPK activation and reducing proinflammatory cytokine expression | Mediators Inflamm. 2019 Apr 30;2019:1897820. |
| Primary bovine mammary epithelial cells | 10, 25, 50 μg/mL | 3 hours pretreatment followed by LPS stimulation for 12 hours | Caffeic acid attenuated LPS-induced structural damage and apoptosis by inhibiting NF-κB and MAPK activation, and reduced proinflammatory cytokine release | Mediators Inflamm. 2019 Apr 30;2019:1897820. |
| BCPAP cells | 16 µg/mL | 48 hours | Inhibited BCPAP cell proliferation with an inhibition rate of ~79% | J Nanobiotechnology. 2024 Sep 18;22(1):571. |
| Rat cortical slices | 100 µM | CA prevented induced loss of reductive capacity, cell damage, and oxidative damage. | Int J Mol Sci. 2023 May 24;24(11):9218. | |
| HEK-Gα15/ETA and HEK-Gα15/ETB cells | 30, 25, 20, 15, 10, 5 and 0 µM | To test the antagonistic activity of the compounds on ETA and ETB receptors. Results showed that these twin drugs could not antagonize ETA and ETB receptors. | Drug Des Devel Ther. 2020 Mar 5;14:977-992. | |
| HEK-Gα15/AT1 cells | 30, 25, 20, 15, 10, 5 and 0 µM | To test the antagonistic activity of compound 1a on Ang II-AT1 receptor, with an IC50 of 340nM. | Drug Des Devel Ther. 2020 Mar 5;14:977-992. | |
| Administration | Dosage | Frequency | Description | References | ||
| Drosophila melanogaster | Dextran sulfate sodium (DSS)-induced ulcerative colitis model | Oral | 0.5 mM and 1 mM | Daily administration for 7 days | CA significantly improved the survival rate of UC flies, restored their motility and digestive abilities, protected intestinal morphology and homeostasis, and reduced intestinal cell damage. Additionally, CA alleviated intestinal damage by inhibiting apoptosis mediated by mitochondrial damage and reducing immune overactivation in the intestine. | Drug Des Devel Ther. 2025 Mar 22;19:2157-2172 |
| C57 mice | S. aureus-induced endometritis model | Intraperitoneal injection | 10, 20, 30 mg/kg | Uterine tissues were harvested 24 hours later | CA significantly alleviated S. aureus-induced uterine injury, MPO activity, the contents of inflammatory factors TNF-α and IL-1β, and NF-κB activation. Meanwhile, CA significantly inhibited S. aureus-induced ferroptosis, as confirmed by decreased MDA and iron concentration and up-regulated GPX4 expression and GSH level. Furthermore, CA attenuated S. aureus-induced HIF-1α and phosphorylated mTOR expression and increased phosphorylated AMPK expression. | J Cell Mol Med. 2024 Oct;28(20):e70175 |
| BALB/c nude mice | Xenograft model | Tail vein injection | 2 mg/kg | 5 times per week for 14 days | Significantly inhibited the volume and weight of human papillary thyroid tumors | J Nanobiotechnology. 2024 Sep 18;22(1):571. |
| Sprague-Dawley rats | D-galactose-induced aging model | Oral gavage | 20 or 40 mg/kg | Once daily for 8 weeks | Caffeic acid alleviates memory and hippocampal neurogenesis deficits induced by D-galactose | Nutrients. 2022 May 23;14(10):2169 |
| ICR mice | E. coli or K. pneumoniae infection model | Oral | 25 or 50 mg/kg/day | Once daily for 10 days | CA pretreatment improved the survival rate of mice and alleviated inflammatory responses and tissue damage in mammary glands. | Front Immunol. 2022 Oct 20;13:1005430. |
| Rats | Alzheimer’s disease model | Oral | 50 mg/kg | Once daily for 25 days | CA significantly counteracted the worsening of cognitive abilities and induced changes in levels of AChE, glutathione, catalase, lipid peroxidation, and superoxide dismutase. | Int J Mol Sci. 2023 May 24;24(11):9218. |
| C57BL/6 mice | LPS-induced sepsis model | Intraperitoneal injection | 50 mg/kg | Single dose, LPS challenge 6 h later | CA significantly improved the survival rate of septic mice, reduced serum IL-1β and TNF-α levels, and inhibited GSDMD activation in peritoneal macrophages | MedComm (2020). 2023 Apr 20;4(3):e255. |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00065715 | Common Cold | Phase 3 | Completed | - | United States, Wisconsin ... 展开 >> University of Wisconsin-Madison Department of Family Medicine Madison, Wisconsin, United States, 53706-1490 收起 << |
| NCT02050334 | Healthy | Phase 1 | Completed | - | United States, Indiana ... 展开 >> IU Health Neuroscience Center Indianapolis, Indiana, United States, 46202 收起 << |
| NCT02050334 | - | Completed | - | - | |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
5.55mL 1.11mL 0.56mL |
27.75mL 5.55mL 2.78mL |
55.51mL 11.10mL 5.55mL |
|
| CAS号 | 331-39-5 |
| 分子式 | C9H8O4 |
| 分子量 | 180.16 |
| SMILES Code | O=C(O)/C=C/C1=CC=C(O)C(O)=C1 |
| MDL No. | MFCD00004392 |
| 别名 | 3,4-Dihydroxycinnamic Acid |
| 运输 | 蓝冰 |
| InChI Key | QAIPRVGONGVQAS-DUXPYHPUSA-N |
| Pubchem ID | 689043 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(582.82 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1